R&D News | pharmaphorum

News

Novartis says novel drug could counter malaria resistance

Novartis has reported what looks like another big step forward in the treatment of malaria, as a drug with a novel mechanism hits the mark in phase 3.

News

FDA unveils swift route to market for personalised drugs

FDA reveals a regulatory pathway for personalised therapies based on 'plausible mechanism', drawing on the bespoke gene-editing treatment of Baby KJ.

News

Change at the top of Recursion as co-founder leaves CEO role

After 12 years as CEO of 'techbio' player Recursion, Chris Gibson is switching to the role of chair and will be replaced by Najat Khan.

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

News